Literature DB >> 12928483

Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies.

Atsushi Iwata1, Mieko Maruyama, Takumi Akagi, Tsutomu Hashikawa, Ichiro Kanazawa, Shoji Tsuji, Nobuyuki Nukina.   

Abstract

Accumulation of insoluble alpha-synuclein aggregates in the brain is characteristic of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Although numerous studies on the aggregation properties of alpha-synuclein have been reported, little is known about its degradation so far. In view of proteolytic degradation, we have found that the serine protease neurosin (kallikrein-6) degrades alpha-synuclein and co-localizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions. In vitro study showed that neurosin prevented alpha-synuclein polymerization by reducing the amount of monomer and also by generating fragmented alpha-synucleins that themselves inhibited the polymerization. Upon cellular stress, neurosin was released from mitochondria to the cytosol, which resulted in the increase of degraded alpha-synuclein species. Down-regulation of neurosin caused accumulation of alpha-synuclein within cultured cells. Thus we concluded that neurosin plays a significant role in physiological alpha-synuclein degradation and also in the pathogenesis of synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928483     DOI: 10.1093/hmg/ddg283

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  62 in total

1.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 2.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

3.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

4.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

5.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

6.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

Review 8.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

Review 9.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

10.  Cerebrospinal fluid proteome of patients with acute Lyme disease.

Authors:  Thomas E Angel; Jon M Jacobs; Robert P Smith; Mark S Pasternack; Susan Elias; Marina A Gritsenko; Anil Shukla; Edward C Gilmore; Carol McCarthy; David G Camp; Richard D Smith; H Shaw Warren
Journal:  J Proteome Res       Date:  2012-08-31       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.